Trials / Completed
CompletedNCT00292721
Effects of Celecoxib After Percutaneous Coronary Intervention
Effects of Celecoxib on Restenosis After Percutaneous Coronary Intervention and Evolution of Atherosclerosis (COREA) Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 260 (estimated)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Several studies including ours have reported that celecoxib improves endothelium-dependent vasodilation and reduces inflammation and neointimal hyperplasia. Our hypothesis is that celecoxib may reduce the late luminal loss after coronary stent implantation (paclitaxel-eluting stent.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Celecoxib | celecoxib: loading and maintenance for 6 months |
Timeline
- Start date
- 2004-08-01
- Primary completion
- 2008-10-01
- Completion
- 2008-10-01
- First posted
- 2006-02-16
- Last updated
- 2011-07-21
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00292721. Inclusion in this directory is not an endorsement.